Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Up 921.9% in April

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the recipient of a significant increase in short interest in April. As of April 15th, there was short interest totalling 191,100 shares, an increase of 921.9% from the March 31st total of 18,700 shares. Based on an average daily volume of 210,400 shares, the short-interest ratio is presently 0.9 days. Currently, 7.6% of the shares of the stock are short sold.

Hedge Funds Weigh In On Vivos Therapeutics

An institutional investor recently bought a new position in Vivos Therapeutics stock. Armistice Capital LLC bought a new stake in Vivos Therapeutics, Inc. (NASDAQ:VVOS) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 57,000 shares of the company’s stock, valued at approximately $709,000. Armistice Capital LLC owned 4.29% of Vivos Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 26.35% of the company’s stock.

Vivos Therapeutics Stock Performance

Shares of NASDAQ:VVOS opened at $2.59 on Friday. The firm has a fifty day moving average price of $4.05 and a 200 day moving average price of $6.74. Vivos Therapeutics has a fifty-two week low of $2.37 and a fifty-two week high of $48.79.

Vivos Therapeutics (NASDAQ:VVOS) last issued its earnings results on Thursday, March 28th. The company reported ($3.05) earnings per share for the quarter. Vivos Therapeutics had a negative return on equity of 665.17% and a negative net margin of 98.42%. The company had revenue of $3.25 million for the quarter.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.